Chenglong Liu

发表

BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer

Z. Shao, Yi Xiao, Di Zhu, 2021, Oncogene.

Discovery of a novel, potent and selective small‐molecule inhibitor of PD‐1/PD‐L1 interaction with robust in vivo anti‐tumour efficacy

K. Yu, Yujun Zhao, Ziqin Yan, 2021, British journal of pharmacology.

Tumor-infiltrated activated B cells suppress liver metastasis of colorectal cancers.

Fan Yang, Zhongen Wu, Dexiang Zhu, 2022, Cell reports.

Clinical cancer immunotherapy: Current progress and prospects

Daizhou Zhang, Ming Chen, Chenglong Liu, 2022, Frontiers in Immunology.

RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers

K. Yu, Zhongen Wu, Ming-cheng Yu, 2022, Journal of experimental & clinical cancer research : CR.

Discovery of a selective and covalent small-molecule inhibitor of BFL-1 protein that induces robust apoptosis in cancer cells.

Yujun Zhao, Jianfeng Lou, Shiyan Zhang, 2022, European journal of medicinal chemistry.

Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin's Interactions with Its Nuclear Partners.

Hao Zhang, Jian-qi Li, Chenglong Liu, 2022, Journal of medicinal chemistry.

Interferon-a potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment.

A. Zhu, S. Qiu, Bo Hu, 2022, Cancer discovery.

Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19

A. von Brunn, Di Zhu, Chenglong Liu, 2020, Medicine in Drug Discovery.

Single-cell transcriptome analysis reveals tumor immune microenvironment heterogenicity and granulocytes enrichment in colorectal cancer liver metastases.

J. Ji, Yunbin Zhang, Zhongwei Zhao, 2020, Cancer letters.

Recent advances in β-catenin/BCL9 protein-protein interaction inhibitors.

Hao Zhang, Qingwei Zhang, Di Zhu, 2021, Future medicinal chemistry.

Discovery of Novel 3-Phenylpiperidine Derivatives Targeting the β-Catenin/B-Cell Lymphoma 9 Interaction as a Single Agent and in Combination with the Anti-PD-1 Antibody for the Treatment of Colorectal Cancer.

Hao Zhang, Yonghui Wang, Li Shen, 2023, Journal of medicinal chemistry.

Design, synthesis and biological evaluation of quercetin derivatives as novel β-catenin/B-cell lymphoma 9 protein-protein interaction inhibitors.

Li Shen, Haopeng Zhang, Jian-qi Li, 2022, European journal of medicinal chemistry.

BCL9 regulates CD226 and CD96 checkpoints in CD8+ T cells to improve PD-1 response in cancer

D. Lambrechts, Zhongen Wu, Ming-Wei Wang, 2021, Signal Transduction and Targeted Therapy.

Targeting Wnt/β-Catenin Pathway for Drug Therapy

Di Zhu, K. Takada, Chenglong Liu, 2020 .

RORγt agonist synergizes with CTLA-4 antibody to inhibit tumor growth through inhibition of Treg cells via TGF-β signaling in cancer.

Di Zhu, Ming-cheng Yu, Qiong Xie, 2021, Pharmacological research.

Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration

Zhongen Wu, Yan Zhou, Chenglong Liu, 2024, Signal transduction and targeted therapy.